Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Read more here.

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Arcus Biosciences (RCUS) announced that Gilead’s (GILD) time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

About the Gilead Collaboration In May 2020, Arcus established a 10-year collaboration with Gilead to strategically advance our portfolio. Under this collaboration, Gilead obtained time-limited ...

Shares of Arcus Biosciences (NYSE:RCUS) hit a new 52-week low on Tuesday after the biotech said that Gilead Sciences’ (NASDAQ:GILD) option rights to partner with the company for a potential ...

BofA lowered the firm’s price target on Arcus Biosciences (RCUS) to $17 from $22 and keeps a Neutral rating on the shares following Gilead’s ...

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company with a market capitalization of $1.2 billion, announced that Gilead Sciences (NASDAQ:GILD)' option ...

With Gilead Sciences Inc. stepping away from its exclusive option rights to casdatifan in treating cancer, Arcus Biosciences Inc. has decided to move on by pricing a $150 million common stock offering ...